The EU marketing authorization application (MAA) for Sanofi Genzyme's olipudase alfa will be reviewed under the European Medicines Agency's accelerated assessment mechanism when the company files for approval.
Olipudase alfa is a potential therapy for the long-term treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease Type B
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?